News Cost of AZ’s new Cambridge HQ ‘has more than doubled’ The cost of AstraZeneca’s new R&D hub and corporate headquarters in Cambridge has swelled to £750 million, more than twice the original estimate, says a report in The Times.
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face